Intravenous Versus Intracoronary Use of Abciximab

• Status: Completed
• Trial end date: 2009-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this study is to investigate wether intracoronary use of bolus Abciximab is superior to intravenous bolus in patients undergoing percutaneous coronary intervention.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Hospital, Gentofte, Copenhagen
• Treatments: Abciximab; Antibodies, Monoclonal; Immunoglobulin Fab Fragments

Criteria

Inclusion Criteria:

• Usually inclusion criteria for Abciximab, that is:

• Adjunct to PCI for the prevention of cardiac ischemic complications:

• In patients undergoing PCI

• In patients with UA not responding to conventional medical therapy when PCI is planned within 24 hours

Exclusion Criteria:

Usually exclusion criteria for Abciximab, that is:

• Active internal bleeding, recent (within 6 weeks) gastrointestinal (GI) or genitourinary (GU) bleeding of clinical significance

• History of cerebrovascular accident (CVA) within 2 years, or CVA with a significant residual neurological deficit

• Bleeding diathesis

• Administration of oral anticoagulants within 7 days unless prothrombin time is less than or equal to 1.2 times control, thrombocytopenia (<100,000 cells/µL)

• Recent (within 6 weeks) major surgery or trauma

• Intracranial neoplasm

• Arteriovenous malformation, or aneurysm

• Severe uncontrolled hypertension

• Presumed or documented history of vasculitis

• Use of intravenous dextran before percutaneous coronary intervention, or intent to use it during intervention

• Known hypersensitivity to any component of this product or to murine proteins.